Robertson Study3
Patients had advanced disease (51% Rai stage III-IV), were also treated with prednisone, and 77% had received prior cytotoxic therapy.
MD Anderson Cancer Center (MDACC) Study8
Patients had advanced disease (58% Rai stage III-IV), and previously had received extensive chemotherapy.Impressive Duration of Response8
Southwest Oncology Group (SWOG) Study
MD Anderson Cancer Center (MDACC) Study
Median duration of disease controlSignificant Improvements in Key Laboratory Values8 †
- 31% increase in hemoglobin
- 63% increase in platelets
Well-Documented Clinical Safety2
The most common adverse events reported with FLUDARA FOR INJECTION are myelosupporession, fever and chills, infection, and nausea and vomiting. Patients should be closely monitored for signs of hematologic and non-hematologic toxicity. Periodic assessment of peripheral blood counts is recommended.
Instances of life-threatening and sometimes fatal autoimmune hemolytic anemia have been reported to occur after one or more cycles of treatment with FLUDARA FOR INJECTION. Patients undergoing treatment with FLUDARA FOR INJECTION should be evaluated and closely monitored for hemolysis. In a clinical investigation using FLUDARA FOR INJECTION in combination with pentostatin (deoxycoformycin) for the treatment of refractory chronic lymphocytic leukemia (CLL), there was an unacceptably high incidence of fatal pulmonary toxicity. Therefore, the use of FLUDARA FOR INJECTION in combination with pentostatin is not recommended.
WARNING: FLUDARA FOR INJECTION should be administered under the supervision of a qualified physician experienced in the use of antineoplastic therapy. FLUDARA FOR INJECTION can severely suppress bone marrow function. When used at high doses in dose-ranging studies in patients with acute leukemia, FLUDARA FOR INJECTION was associated with severe neurologic effects, including blindness, coma, and death. This severe central nervous system toxicity occurred in 36% of patients treated with doses approximately four times greater (96 mg/m2/day for 5 to 7 days) than the recommended dose. Similar severe central nervous system toxicity has been rarely (less than or equal to 0.2%) reported in patients treated at doses in the range of the dose recommended for chronic lymphocytic leukemia.
* For patients with alkylating-agent refractory B-cell CLL.
† Mean hemoglobin levels (g/dL) and platelet counts (mm3) in subsets of responders with low baseline levels.
Please see full Prescribing Information for FLUDARA®.
Distributed by Bayer HealthCare Pharmaceuticals Inc., Wayne, NJ 07470
Manufactured by Ben Venue Laboratories, Bedford, OH 44146
